Clinical trials: Invasive Breast Carcinoma
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Breast Carcinoma, Metastatic Breast Cancer
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases
- Conditions
- Breast Carcinoma, Metastatic Breast Cancer, Invasive Breast Cancer, Distant Metastases.Pathology
- Trial name
- NCT03970967
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Russia
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Invasive Breast Cancer
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.
- Trial name
- NCT03564782
- Testing
- PVSRIPO
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Istari Oncology, Inc.
Breast Cancer, Invasive Breast Cancer
Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients
This study aims to investigate the role of a mobile health app, Outcomes4Me, in the navigation of care for people with breast cancer.
- Conditions
- Breast Cancer, Invasive Breast Cancer, Metastatic Breast Cancer, Breast Carcinoma
- Trial name
- FIONA (NCT04262518)
- Testing
- Outcomes4Me Mobile App
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Outcomes4Me
Primary Invasive Breast Cancer
EndoPredict® Extended Endocrine Trial (EXET)
The purpose of this study is to evaluate the impact of using EndoPredict® clinically to inform treatment decisions for extended endocrine therapy, and the subsequent impact on patient outcomes.
- Trial name
- NCT04016935
- Testing
- Observational
- Where
- 52 sites in United States
- Volunteers
- 855 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02587689
- Testing
- anti-MUC1 CAR T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02839954
- Testing
- anti-MUC1 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Breast Cancer, Ovarian Function
Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy
Primary objective of this study is to determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing adjuvant chemotherapy for primary invasive breast cancer by…
- Trial name
- PROOF (NCT00888082)
- Testing
- Goserelin acetate
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Breast Cancer, Breast Cancer Female
Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC
A central challenge in the fight against breast cancer is how to detect disease in a noninvasive manner before it is detectable by imaging methods.
- Trial name
- NCT03480659
- Where
- Kazakhstan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- HKGepitherapeutics
Breast Cancer
Breast Cancer Index (BCI) Registry
The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in…
- Trial name
- NCT04875351
- Testing
- Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
- Where
- 105 sites in United States
- Volunteers
- 3,465 people
- Sponsor
- Biotheranostics, Inc.
Colorectal Cancer, Epithelial Ovarian Cancer
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer…
- Conditions
- Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma
- Trial name
- NCT07432633
- Testing
- [18F]FPyQCP
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Blue Earth Diagnostics
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence.
- Trial name
- NCT04622319
- Testing
- DS-8201a, T-DM1
- Where
- 482 sites in United States, Argentina and 29 more
- Volunteers
- 1,600 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
The purpose of this randomized Phase III study is to determine whether preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large…
- Trial name
- Medifocus301 (NCT01204801)
- Testing
- Focused Microwave Thermotherapy, Chemotherapy (control)
- Where
- 2 sites in United States, Canada
- Volunteers
- 238 people
- Sponsor
- Medifocus, Inc.
Breast Neoplasms
Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen \& are switched to Aromasin®…
- Trial name
- NCT01176916
- Testing
- Aromasin (exemestane)
- Where
- 53 sites in China
- Volunteers
- 564 people
- Sponsor
- Pfizer
Invasive Ductal Carcinoma, Ductal Carcinoma in Situ
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer.
- Trial name
- NCT01644669
- Testing
- Intra-operative Radiation Therapy - IORT
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Xoft, Inc.
Metastatic Breast Cancer
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
- Trial name
- Dauntless-1 (NCT04115306)
- Testing
- PMD-026, fulvestrant
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Phoenix Molecular Designs
Breast Cancer, DCIS
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by…
- Conditions
- Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
- Trial name
- NCT05900986
- Testing
- LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Integro Theranostics
Lung Cancer, Breast Cancer
Non Invasive Detection of Lung and Breast Cancer by Odor Signature
The investigators have developed an early detection solution for lung and breast cancer. A system which can distinguish between different medical odors based on biosensors.
- Trial name
- NCT02195076
- Testing
- non-invasive detection of cancer odor
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- BioSense Medical LTD